 | | Cardiovascular Exchange Summit 2011 |
|  | | Major clinical outcome trials of RAAS manipulation |
|
 | | Where are we now? |
|  | | Angiotensin-receptor blockade and risk of cancer |
|
 | | ARB and cancer occurrence |
|  | | ARB and cancer deaths |
|
 | | Antihypertensive drugs and risk of cancer |
|  | | Network meta-analyses |
|
 | | ARBs and cancer risk |
|  | | Use of Angiotensin Receptor Blockers and the Risk of Cancer |
|
 | | EMA opinion ARBs |
|  | | Where are we now? |
|
 | | Elevated plasma renin activity is associated with increased risk of MI |
|  | | VAL-HeFT trial |
|
 | | Prognostic value of renin |
|  | | Prorenin and Heart Failure |
|
|
|
 | | Cardiospecific overexpression of (P)RR |
|  | | Isoprenalin |
|
 | | Prorenin, Renin, and Their Receptor |
|  | | Renin- and prorenin-induced effects |
|
 | | (Pro)Renin receptor |
|  | | Where are we now? |
|
 | | Aliskiren |
|  | | ASPIRE |
|
 | | ASPIRE |
|  | | ASPIRE |
|
 | | ASPIRE |
|  | | Progression of left ventricular dysfunction |
|
 | | SAVE—Results of the Survival and Ventricular Enlargement Trial |
|  | | All-Cause Mortality |
|
 | | Effect of captopril |
|  | | The SAVE Study |
|
 | | Meta-analysis of Remodeling Trials |
|  | | Absence of CHF in patients after AMI |
|
 | | Ventricular dilatation and infarct size |
|  | | ASPIRE |
|
 | | Conclusions |
|
Deel deze pagina met collega's en vrienden: